This time last year, Athenex Inc. was fresh off its IPO, which grossed $66 million, and embarking on an ambitious strategy to conduct phase III trials of Oraxol, the lead chemotherapeutic from its Orascovery platform, in metastatic breast cancer (MBC) and the phase III program for KX-01, the lead candidate from its Src kinase inhibition platform, to treat actinic keratosis (AK). The Buffalo, N.Y.-based company delivered everything promised in the IPO on time or ahead of schedule, according to CEO Johnson Lau. (See BioWorld Today, June 7, 2017.)